advertisement
Milea D 18
Showing records 1 to 18 | Display all abstracts from Milea D106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Chiquet C
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Gunasekeran DV
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Vignal C
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Zheng F; Lim GYS
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Gohier P; Heron E
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Chong CCY; Zhang S
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Thuret G
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Ng WY
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Rougier MB; Lehmann A
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Keel S
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Flet L
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Xiang Y; Park KH
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Quesada JL; Roustit M
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Park SJ; Chandra A
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Milea D
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Wu L
Frontiers in medicine 2022; 9: 875242
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Pepin JL;
Trials 2022; 23: 916
106225 Acceptance and Perception of Artificial Intelligence Usability in Eye Care (APPRAISE) for Ophthalmologists: A Multinational Perspective
Campbel JP; Lee AY; Keane PA; Denniston A; Lam DSC; Fung AT; Chan PRV; Sadda SR; Loewenstein A; Grzybowski A; Fong KCS; Wu WC; Bachmann LM; Zhang X; Yam JC; Cheung CY; Pongsachareonnont P; Ruamviboonsuk P; Raman R; Sakamoto T; Habash R; Girard M; Milea D; Ang M; Tan GSW; Schmetterer L; Cheng CY; Lamoureux E; Lin H; Van Wijngaarden P; Wong TY; Ting DSW
Frontiers in medicine 2022; 9: 875242
